An observational study in Pain, sponsored by HALEON. Not yet recruiting at 1 site in Singapore. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by HALEON · Observational
Among 23 studies in Pain with a site in Singapore — 4 open to participants now, 7 under way, 2 of them phase 3. Pain · Singapore.
Among the 23 studies in Pain with a site in Singapore, this one is one of 3 that started in 2026, is one of 6 observational ones, and was the 23rd registered.
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →4 of the 23 studies in Pain with a site in Singapore are open now. Recruiting first, the newest first:
Nanyang Technological University · Sites in Singapore
Ages 16–35 · Women only
KK Women's and Children's Hospital · Sites in Singapore
Ages 21–70 · Women only
HALEON · Sites in Singapore
Ages 18+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 100 across 1,252 observational studies indexed under Pain.
Median enrollment 63 across the 17 interventional studies, 475 across the 6 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
HALEON has 9 studies filed under Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Pain with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07931859HALEONA Retrospective Study to Assess Patient-Reported Treatment Experience With Over-the-Counter Analgesic Products | 2026-12 |
| NCT03415620KK Women's and Children's HospitalPerioperative Music Listening on Anxiety, Pain, Analgesia Use and Patient Satisfaction | 2026-12-31 |
| NCT07909590HALEONA Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning | 2027-01 |
| NCT03685422KK Women's and Children's HospitalPreoperative Virtual Reality to Reduce Pain on Gynaecologic Patients Undergoing Surgery | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Pain with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the self-reported perceived onset and effectiveness of pain (headache/muscle ache) relief in overweight and obese adults currently on Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) therapy who have used Panadol Advance or Panadol ActiFast (or local equivalent variant) for occasional pain (headache/ muscle ache) relief in the past 1 month.
This is a real-world, observational, cross-sectional survey study of 600 participants aged 18-65 years old from the United Kingdom, Sweden, Colombia and Australia, who self-report using Panadol Advance or ActiFast (or local equivalent variant) for occasional pain relief in the past 1 month. Once eligibility is confirmed, participants will be directed to complete an online survey designed to gather data relevant to the research objectives.
Resident of Australia/ United Kingdom/ Sweden/ Colombia who selfreport using Panadol Advance or ActiFast (or local equivalent variant) for occasional pain relief in the past 1 month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have used Panadol Advance or Panadol ActiFast (or local equivalent variant) for occasional pain (headache/ muscle ache) relief in the past one month.
Drug: Paracetamol
Paracetamol 500 milligram (mg) taken orally.
Perceived Onset of Relief After Product Use
Thinking about the recent pain episode, participants will report approximate time for their pain to decrease after using the product.
Time frame: Within the past 1 month from time of participation
Perceived Relief From Product Use
Thinking about the recent pain episode, participants will describe the first sign of symptom relief they perceived after using the product.
Time frame: Within the past 1 month from time of participation
Characterization of the Pain Profile
The information on pain such as type, frequency, severity, and duration will be collected from the participants.
Time frame: Within the past 1 month from time of participation
Quality of Life (QoL) Assessment Before and After Using the Product Post for Occasional Pain
Thinking about most recent pain episode, participants will be asked to respond to QoL questions related to effect of pain on the aspects of their daily life before and after using the product. The responses will be scored using a 5-point scale, where 1= Not at all, and 5= Significantly. Lower score indicates better quality of life.
Time frame: Within the past 1 month from time of participation
Sources of Product Information and Trust in Product
The information around sources of product information and how much does participants trust the product for mild to moderate or occasional pain relief will be collected.
Time frame: Within the past 1 month from time of participation
Product Switch Behaviors
The information around the reasons for switching from the other brands will be collected.
Time frame: Within the past 1 month from time of participation
Perceived Difference in Speed of Analgesia Onset
Participants will respond to a question- Compared with other brand(s) used in the past, how quickly does this product begin to relieve headache/ muscle ache. Response will be scored on scale 1= much faster to 5= much slower.
Time frame: Within the past 1 month from time of participation
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.